SCHEMBL29319089

SCHEMBL29319089

CC(C)(C)OC(=O)N1CCN(C2COC3(CCN(C(=O)OCc4ccccc4)CC3)C2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MGLL Q99685 2/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GPR119 Q8TDV5 1/20 0.43
STS P08842 1/20 0.43
CYP2C19 P33261 1/20 0.42
TACR1 P25103 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
ENPP2 Q13822 1/20 0.41
ATXN2 Q99700 1/20 0.41
PARP1 P09874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29319166 0.88 CYP2D6 (0.46) MGLLGPR119STSOPRD1OPRK1
SCHEMBL21981373 0.85 ENPP2 (0.48) HTTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL25603204 0.85 ENPP2 (0.48) HTTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL27162616 0.82 SMN1; SMN2 (0.49) HTTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL30655482 0.82 GPR119 (0.47) MGLLMEN1KMT2ANPSR1GPR119
SCHEMBL19692934 0.82 MGLL (0.46) HTTSMN1; SMN2NPC1RAB9AMGLL
SCHEMBL29609824 0.82 MGLL (0.46) HTTSMN1; SMN2NPC1RAB9AMGLL
SCHEMBL29608793 0.82 MGLL (0.46) HTTSMN1; SMN2NPC1RAB9AMGLL
SCHEMBL119649 0.82 SMN1; SMN2 (0.58) HTTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL21458909 0.82 SMN1; SMN2 (0.52) HTTSMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634169-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF Pfizer Inc. (US) 2025-10-22 EP disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed
WO-2024127297-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF PFIZER INC. (US) 2024-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders HSD17B13, HSD17B3, HSD17B1 HTT 883/4885SMN1; SMN2 3649/4885NPC1 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.